阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

未开盘 12-18 16:00:00 EST

64.64

-2.54

-3.78%

盘后64.53

-0.11-0.17%

19:42 EST

最高66.42	最低64.62	成交量713.31万
今开65.93	昨收67.18	日振幅2.68%
总市值2,004亿	流通市值1,997亿	总股本31.01亿
成交额4.67亿	换手率0.23%	流通股本30.90亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":64.64,"timestamp":1734555600000,"preClose":67.18,"halted":0,"volume":7133057,"hourTrading":{"tag":"盘后","latestPrice":64.53,"preClose":64.64,"latestTime":"19:42 EST","volume":1711965,"amount":110661782.2254,"timestamp":1734568965537},"delay":0,"floatShares":3089881428,"shares":3100574690,"eps":2.075055,"marketStatus":"未开盘","marketStatusCode":0,"change":-2.54,"latestTime":"12-18 16:00:00 EST","open":65.93,"high":66.42,"low":64.62,"amount":467070860.42632,"amplitude":0.026794,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.075055,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734598800000},"adr":1,"listingDate":737179200000,"adjPreClose":67.18,"adrRate":0.5,"dividendRate":0.022973,"preHourTrading":{"tag":"盘前","latestPrice":65.9,"preClose":67.18,"latestTime":"09:29 EST","volume":523154,"amount":34466505.069560006,"timestamp":1734532169349},"postHourTrading":{"tag":"盘后","latestPrice":64.53,"preClose":64.64,"latestTime":"19:42 EST","volume":1711965,"amount":110661782.2254,"timestamp":1734568965537},"volumeRatio":1.18798,"optionData":{"bulkOrders":[{"symbol":"AZN","call":true,"expireDate":1740114000000,"strike":"75.0","timestamp":1734537261345,"price":0.44999998807907104,"volume":2545,"amount":114525,"type":"-"}]},"impliedVol":0.2687,"impliedVolPercentile":0.7968},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2492900039","title":"结果超预期，阿斯利康“救命药”仍被FDA拒批？","url":"https://stock-news.laohu8.com/highlight/detail?id=2492900039","media":"健识局","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492900039?lang=zh_cn&edition=full","pubTime":"2024-12-18 20:16","pubTimestamp":1734524162,"startTime":"0","endTime":"0","summary":"近日，阿斯利康宣布，FDA拒绝了旗下药物Andexxa的完全批准。对此，阿斯利康表示，Andexxa目前还不会退出美国市场，公司将进一步收集药物安全性和疗效方面的数据以回应FDA的质疑。继续寻求全面批准一些业内人士认为，FDA的这次拒批多少有些意外。结果发现，Andexxa提前达到了临床终点，其效果比研究预期的时间更早显现出来，阿斯利康还因此提前结束了临床，以更快提交全面批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218203600a1f8890f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218203600a1f8890f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU2456880835.USD","LU0320765992.SGD","LU1829250122.USD","LU2462157665.USD","AZN","LU0889565916.HKD","LU0109394709.USD","LU2417539215.USD","BK4588","BK4585","LU2236285917.USD","BK4007"],"gpt_icon":0},{"id":"2492924221","title":"阿斯利康任命Arm首席执行官为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2492924221","media":"港股那点事","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492924221?lang=zh_cn&edition=full","pubTime":"2024-12-18 13:54","pubTimestamp":1734501240,"startTime":"0","endTime":"0","summary":"格隆汇12月18日｜12月17日，阿斯利康宣布任命半导体公司Arm首席执行官雷内·哈斯为阿斯利康非执行董事，作为阿斯利康董事会改组的一部分。哈斯将于2025年1月1日正式加入公司董事会，也成为首位加盟阿斯利康的半导体行业高管。另一位被任命的非执行董事是瑞士听力医疗公司Sonova的首席财务官Birgit Conix，她将于明年2月1日加入阿斯利康董事会。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-12-18/doc-inczwiqx7804863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","ARM","LU0889565916.HKD","BK4588","BK4007","LU0109394709.USD","AZN","LU0348723411.USD","IE00BMPRXQ63.HKD","IE00BMPRXN33.USD","LU2456880835.USD","LU2417539215.USD","BK4141","LU2462157665.USD","BK4568","LU2236285917.USD","IE00BMPRXR70.SGD","LU0320765992.SGD","LU1829250122.USD"],"gpt_icon":0},{"id":"2492924834","title":"Arm CEO加盟！阿斯利康董事会迎首位半导体行业高管","url":"https://stock-news.laohu8.com/highlight/detail?id=2492924834","media":"第一财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492924834?lang=zh_cn&edition=full","pubTime":"2024-12-18 13:40","pubTimestamp":1734500400,"startTime":"0","endTime":"0","summary":"哈斯将于2025年1月1日正式加入公司董事会，也成为首位加盟阿斯利康的半导体行业高管。Arm和阿斯利康总部都位于英国剑桥。随着阿斯利康四名现任非执行董事任期将在未来几年内到期，该公司正在对董事会进行改组。与哈斯同时被任命的另一位非执行董事是瑞士听力医疗公司Sonova的首席财务官Birgit Conix，她将于明年2月1日加入阿斯利康董事会。阿斯利康对董事会成员的最新任命也体现了其多元化战略。过去三个月来，阿斯利康股价下跌超过12%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218134337ab80fb0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"c2770f97c2b01bee55717747f9330cf6","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218134337ab80fb0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4141","LU2236285917.USD","AZN","LU2462157665.USD","IE00BMPRXR70.SGD","BK4568","LU0889565916.HKD","ARM","IE00BMPRXQ63.HKD","BK4585","LU1829250122.USD","LU0109394709.USD","LU2456880835.USD","LU2417539215.USD","BK4007","LU0348723411.USD","IE00BMPRXN33.USD","LU0320765992.SGD","BK4588"],"gpt_icon":1},{"id":"2490873384","title":"睿昂基因实控人熊慧姐弟涉诈骗罪被捕 或卷入阿斯利康骗保案股价三年半跌84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490873384","media":"长江商报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490873384?lang=zh_cn&edition=full","pubTime":"2024-12-12 10:55","pubTimestamp":1733972131,"startTime":"0","endTime":"0","summary":"此前，睿昂基因副总经理何俊彦、副总经理薛愉玮因涉嫌诈骗罪被刑事拘留。有消息称，睿昂基因熊慧等4人所涉嫌“诈骗罪”或与阿斯利康骗保案有关。10月26日，睿昂基因发布公告称，近日，公司收到以上四人家属通知，熊慧、熊钧、薛愉玮、何俊彦的强制措施变更为刑事拘留，涉嫌罪名变更为诈骗罪。截至2024年12月11日收盘，睿昂基因股价达21.28元/股，约三年半时间下跌约84%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212110717ab713eb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212110717ab713eb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU0889565916.HKD","BK4007","LU2417539215.USD","688217","LU2462157665.USD","LU0320765992.SGD","LU2236285917.USD","LU1829250122.USD","BK4568","AZN","LU0109394709.USD","LU2456880835.USD","BK4588"],"gpt_icon":0},{"id":"2490174498","title":"阿斯利康(AZN.US)和默沙东(MRK.US)公布3期临床试验OlympiA的长期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2490174498","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490174498?lang=zh_cn&edition=full","pubTime":"2024-12-12 07:56","pubTimestamp":1733961417,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康和默沙东今日公布了3期临床试验OlympiA的长期结果。Lynparza则是一种“first-in-class\"的PARP抑制剂，也是首个合成致死靶向治疗药物，用于靶向带有同源重组修复缺陷的细胞/肿瘤。基于3期临床试验OlympiA的结果，Lynparza已在美国、欧盟、日本及许多其他国家和地区获批，用于治疗gBRCAm、HER2阴性高危早期乳腺癌。此外，它还获批在美国、欧盟、日本及许多其他国家和地区用于治疗gBRCAm、HER2阴性转移性乳腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4534","BK4588","LU2468319806.SGD","LU2089984988.USD","LU0211331839.USD","LU1829250122.USD","LU1974910355.USD","IE0002141913.USD","IE00B2B36J28.USD","LU1989772840.SGD","SG9999001176.SGD","LU2361045086.USD","SG9999001440.SGD","SG9999013999.USD","IE00BJJMRZ35.SGD","LU1037948541.HKD","LU2023250843.SGD","LU2106854487.HKD","03347","LU0861579265.USD","LU1983299246.USD","LU1934455277.USD","LU2461242641.AUD","BK1576","LU0965509010.AUD","LU1066051498.USD","BK4007","LU2324357040.USD","LU1023059063.AUD","IE00BSNM7G36.USD","AZN","LU0208291251.USD","LU1066051225.USD","LU1093756325.SGD","LU1934455863.HKD","BK4516","LU0266013472.USD","LU0889565916.HKD","SG9999014567.USD","SG9999015358.SGD","LU1989771016.USD","LU0234572021.USD","LU1917777945.USD","LU0203345920.USD","LU0320765992.SGD","LU2456880835.USD","LU2236285917.USD","LU0006306889.USD","IE0009355771.USD","MRK"],"gpt_icon":0},{"id":"2490090151","title":"阿斯利康(AZN)：美国FDA授予Trop2靶向抗体偶联药物突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2490090151","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490090151?lang=zh_cn&edition=full","pubTime":"2024-12-10 20:59","pubTimestamp":1733835555,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康(AZN)和第一三共宣布，美国FDA授予其Trop2靶向抗体偶联药物(ADC)datopotamab deruxtecan(Dato-DXd)突破性疗法认定(BTD)，用于治疗携带局部晚期或转移性表皮生长因子受体突变(EGFRm)的非小细胞肺癌(NSCLC)成人患者，这些患者在接受EGFR酪氨酸激酶抑制剂(TKI)和铂类化疗后疾病仍出现进展。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/MjAwNTQ3MTMzNWUxMDE3ODY5MDY1MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjAwNTQ3MTMzNWUxMDE3ODY5MDY1MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"283035","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU2456880835.USD","LU0320765992.SGD","LU2462157665.USD","BK4585","LU2236285917.USD","LU2417539215.USD","LU1829250122.USD","AZN","LU0109394709.USD","BK4007","LU0889565916.HKD","BK4588"],"gpt_icon":0},{"id":"2490592052","title":"阿斯利康(AZN.US)潜在重磅ADC获突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2490592052","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490592052?lang=zh_cn&edition=full","pubTime":"2024-12-10 14:10","pubTimestamp":1733811019,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康和第一三共宣布，美国FDA授予其Trop2靶向抗体偶联药物datopotamab deruxtecan突破性疗法认定，用于治疗携带局部晚期或转移性表皮生长因子受体突变的非小细胞肺癌成人患者，这些患者在接受EGFR酪氨酸激酶抑制剂和铂类化疗后疾病仍出现进展。根据新闻稿，这是datopotamab deruxtecan首次获得突破性疗法认定。此次FDA授予突破性疗法认定主要是基于TROPION-Lung05临床2期试验数据，并加上TROPION-Lung01临床3期试验的支持性数据。18例患者中有10名(56%)出现脑部肿瘤直径总和缩小。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","BK4568","LU1829250122.USD","AZN","BK4585","ADC","LU2236285917.USD","BK4080","LU0889565916.HKD","LU0320765992.SGD","LU2462157665.USD","BK4007","BK4231","LU2417539215.USD","BK4588","LU2456880835.USD"],"gpt_icon":0},{"id":"2490923527","title":"医药行业研究：阿斯利康DURVALUMAB获FDA批准 用于治疗LS-SCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2490923527","media":"太平洋证券股份...","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490923527?lang=zh_cn&edition=full","pubTime":"2024-12-09 00:00","pubTimestamp":1733673600,"startTime":"0","endTime":"0","summary":"行业要闻：12 月6 日，阿斯利康宣布其重磅PD-L1 抑制剂Imfinzi已获得美国FDA 的批准，用于治疗接受铂类同步放化疗后病情未进展的局限期小细胞肺癌成人患者。Durvalumab 是一种人源化的单克隆抗体， 通过与PD-L1 的结合，durvalumab 阻断PD-L1 与PD-1 和CD80 蛋白的结合，进而抑制肿瘤的免疫逃逸机制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209120209ab68bd3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209120209ab68bd3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU2236285917.USD","BK4585","LU0109394709.USD","LU0320765992.SGD","LU1829250122.USD","LU2456880835.USD","BK4568","LU2462157665.USD","LU0889565916.HKD","LU2417539215.USD","BK4588","AZN"],"gpt_icon":0},{"id":"2489845012","title":"“肿瘤检测龙头”实控人姐弟被捕！睿昂基因被曝涉阿斯利康“骗保”案","url":"https://stock-news.laohu8.com/highlight/detail?id=2489845012","media":"市场资讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489845012?lang=zh_cn&edition=full","pubTime":"2024-12-06 20:18","pubTimestamp":1733487480,"startTime":"0","endTime":"0","summary":"　　因涉嫌诈骗被刑拘的“肿瘤检测龙头”4名高管“状态更新”。　　7月被指定居住监视，10月被刑事拘留。12月5日，睿昂基因公告实控人姐弟——熊慧、熊钧，因涉嫌诈骗罪被已被批捕。　　据“界面新闻”报道，睿昂基因4高管所涉案件，与阿斯利康骗保案有关。　　截至12月6日收盘，睿昂基因股价报21元/股，下跌3.36%，总市值12亿元。　　睿昂基因并未披露4名高管涉案详情。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-12-06/doc-incypsye5396810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4568","688217","LU0109394709.USD","BK4588","BK4585","AZN","LU1829250122.USD","LU0320765992.SGD","LU2456880835.USD","LU0889565916.HKD","BK4007","LU2417539215.USD","LU2236285917.USD","BK0239","LU2462157665.USD"],"gpt_icon":0},{"id":"2489179474","title":"阿斯利康“度伐利尤单抗”新适应症获 FDA 批准上市，针对局限期小细胞肺癌！","url":"https://stock-news.laohu8.com/highlight/detail?id=2489179474","media":"市场资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489179474?lang=zh_cn&edition=full","pubTime":"2024-12-06 12:49","pubTimestamp":1733460540,"startTime":"0","endTime":"0","summary":"12月5日，阿斯利康公布，其 PD-L1单抗度伐利尤单抗新适应症在美获FDA批准，用于治疗在同时进行铂类化疗和放射治疗后病情未进展的局限期小细胞肺癌  的成年患者，成为首个也是唯一一个针对 LS-SCLC 的免疫治疗方案。此次获批是基于 ADRIATIC III 期临床试验结果。基于 PFS 比较，Imfinzi 相比安慰剂将疾病进展或死亡风险降低了 24%。接受 Imfinzi 治疗的患者的中位 PFS 为 16.6 个月，而安慰剂组为 9.2 个月。2017 年 5 月，Imfinzi 首次被美国 FDA 批准上市，用于已接受治疗的晚期膀胱癌患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-06/doc-incypaar2089260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2417539215.USD","BK4007","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4568","LU2236285917.USD","BK4585","LU2462157665.USD","BK4588","AZN","LU1829250122.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2489441253","title":"Iskra接棒王磊不久 阿斯利康中国高层启动重大人事调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2489441253","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489441253?lang=zh_cn&edition=full","pubTime":"2024-12-06 08:43","pubTimestamp":1733445790,"startTime":"0","endTime":"0","summary":"12月4日晚，阿斯利康宣布了多项重要的人事任命。其中，全球执行副总裁、国际业务负责人职务由IskraReic接替。值得注意的是，Iskra接替的正是此前因在中国接受调查而继续暂离工作岗位的王磊。资料显示，Iskra于2001年加入阿斯利康，此后在公司内担任过多个领导职务，包括全球执行副总裁、欧洲和加拿大负责人，并于2021年起担任全球执行副总裁、疫苗和免疫疗法业务负责人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412063260789969.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412063260789969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1591","BK1501","LU0889565916.HKD","BK1247","00241","LU2417539215.USD","LU2236285917.USD","BK1515","LU2462157665.USD","BK4588","AZN","LU1829250122.USD","BK1571","BK1610","LU2456880835.USD","BK1142","BK1589","BK1584","BK1502","LU0320765992.SGD","BK4585","LU0109394709.USD","BK1189","BK4007","BK4568"],"gpt_icon":0},{"id":"2489844822","title":"金十数据整理：每日科技要闻速递（12月3日）","url":"https://stock-news.laohu8.com/highlight/detail?id=2489844822","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489844822?lang=zh_cn&edition=full","pubTime":"2024-12-06 07:30","pubTimestamp":1733441433,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["3NVD.UK","SG9999001424.SGD","NVDS.UK","LU0109391861.USD","NVDA","AZN","NVDX","TWmain","LU0345768740.USD","NVD2.UK","LU1035775433.USD","NVD3.UK","LU0823421416.USD","2NVD.UK","161028","LU2125909916.SGD","NVDD","03145","SNVD.UK","LU1988902786.USD","LU0320765992.SGD","NVDU","NVDY","161631","TSM","LU1267930813.SGD","LU0234572021.USD","IE00BJJMRX11.SGD","IE00BJTD4V19.USD","LU1066053197.SGD","NVD","IE00BQXX3C00.GBP","LU2092937148.SGD","LU2491050071.SGD","LU0792757196.USD","IE00BMPRXR70.SGD","LU0265550359.USD","LU0170899867.USD","LU1804176565.USD","NVDS","NVDL","159813","LU0316494557.USD","IE00BK4W5L77.USD","EWT","LU2097344357.USD","LU2456880835.USD","399417"],"gpt_icon":0},{"id":"2489344431","title":"阿斯利康王磊接任者出炉！年内多家跨国药企现人事变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2489344431","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489344431?lang=zh_cn&edition=full","pubTime":"2024-12-05 18:56","pubTimestamp":1733396182,"startTime":"0","endTime":"0","summary":"12月4日晚间，跨国药企阿斯利康宣布任命IskraReic为全球执行副总裁、国际业务负责人，全面负责包括中国、亚洲和欧亚市场、中东和非洲、拉丁美洲、澳大利亚和新西兰在内的整体战略。阿斯利康进一步表示，Iskra将接替王磊的工作，而王磊因在中国接受调查而继续暂离工作岗位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412053260388518.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412053260388518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1571","BK1142","BK1591","BK4007","LU0889565916.HKD","BK1501","LU2236285917.USD","LU2462157665.USD","BK4588","LU0109394709.USD","BK1589","BK4585","BK1247","BK1502","BK1189","BK1610","LU0320765992.SGD","BK1515","LU2417539215.USD","00241","BK1584","AZN","LU1829250122.USD","LU2456880835.USD","BK4568"],"gpt_icon":0},{"id":"2489443908","title":"FDA批准阿斯利康(AZN)畅销药物Imfinzi上市 拟用于治疗有限期小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2489443908","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489443908?lang=zh_cn&edition=full","pubTime":"2024-12-05 18:41","pubTimestamp":1733395304,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美国食品药品监督管理局(FDA)周三表示，已批准阿斯利康(AZN)上市重磅药物Imfinzi，拟用于治疗部分成人有限期小细胞肺癌。这种化学上被称为durvalumab的治疗方法被批准用于接受化疗和放疗后疾病没有恶化的患者。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"282817","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU2456880835.USD","BK4588","LU0109394709.USD","LU2417539215.USD","LU2462157665.USD","AZN","BK4007","LU0889565916.HKD","LU1829250122.USD","BK4585","LU2236285917.USD","BK4568"],"gpt_icon":0},{"id":"2489152481","title":"FDA批准阿斯利康(AZN.US)畅销药物Imfinzi治疗有限期小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2489152481","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489152481?lang=zh_cn&edition=full","pubTime":"2024-12-05 16:20","pubTimestamp":1733386851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国食品药品监督管理局周三表示，已批准阿斯利康上市重磅药物Imfinzi用于治疗部分成人有限期小细胞肺癌。这种化学上被称为durvalumab的治疗方法被批准用于接受化疗和放疗后疾病没有恶化的患者。Imfinzi是一种人类单克隆抗体，可以阻断肿瘤逃避和抑制免疫系统的能力，同时增强人体的抗癌免疫反应，为毒性化疗提供了另一种选择。Imfinzi被批准用于治疗多种类型的癌症，包括广泛期小细胞肺癌、胆管癌和非小细胞肺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU0109394709.USD","LU2456880835.USD","LU2236285917.USD","LU0320765992.SGD","AZN","BK4588","LU2462157665.USD","BK4585","LU2417539215.USD","LU1829250122.USD","BK4568","LU0889565916.HKD"],"gpt_icon":0},{"id":"2489848217","title":"阿斯利康王磊接受调查离岗一个月后：接替者敲定，中国团队调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2489848217","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489848217?lang=zh_cn&edition=full","pubTime":"2024-12-05 15:43","pubTimestamp":1733384607,"startTime":"0","endTime":"0","summary":"蓝鲸新闻12月5日讯 10月30日，阿斯利康证实时任全球执行副总裁、国际业务主席及中国总裁王磊先生正在中国配合调查。事隔约一个月后，12月4日，阿斯利康宣布任命Iskra Reic为全球执行副总裁、国际业务负责人，全面负责包括中国、亚洲和欧亚市场、中东和非洲、拉丁美洲、澳大利亚和新西兰在内的这一 广袤地区整体战略，推动业务实现可持续增长。蓝鲸财经获悉，Iskra Reic的工作地会是在上海，此外，中国团队其他成员也有调整。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/246265","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0889565916.HKD","BK4585","BK1502","AZN","BK1589","BK1584","BK4568","BK4588","00241","BK1610","BK1591","LU2462157665.USD","LU2236285917.USD","LU0109394709.USD","LU0320765992.SGD","BK1571","BK1189","LU2417539215.USD","BK1142","BK1501","LU1829250122.USD","BK1515","BK1247","BK4007","LU2456880835.USD"],"gpt_icon":0},{"id":"2489449103","title":"阿斯利康中国迎来新领导，接下来做什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2489449103","media":"财经杂志","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489449103?lang=zh_cn&edition=full","pubTime":"2024-12-05 11:36","pubTimestamp":1733369794,"startTime":"0","endTime":"0","summary":"原阿斯利康中国总经理赖明隆，担任阿斯利康全球肿瘤业务Dato-DXd及肺癌事业部负责人。第三项是，11月6日，阿斯利康在一场投资者交流活动中表示，一些雇员正面临非法进口药品和窃取隐私数据的调查。阿斯利康有员工涉嫌非法将某些肿瘤药物进口到中国内地接受调查，其中涉两名现任和两名前高级管理人员。截至目前，已公开的部分判决书显示，阿斯利康骗保案涉案百余人。目前，尚未见到阿斯利康对此的公开回应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205113934a1d5442d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205113934a1d5442d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","BK4588","BK4568","AZN","LU2462157665.USD","LU1829250122.USD","LU0320765992.SGD","BK4585","LU2417539215.USD","LU2236285917.USD","LU0889565916.HKD","LU2456880835.USD","BK4007"],"gpt_icon":0},{"id":"2489510877","title":"阿斯利康中国人事调整 林骁出任阿斯利康中国总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2489510877","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489510877?lang=zh_cn&edition=full","pubTime":"2024-12-05 11:28","pubTimestamp":1733369333,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","LU1829250122.USD","LU2417539215.USD","BK4585","LU2462157665.USD","LU2456880835.USD","LU2236285917.USD","BK4588","AZN","BK4568","BK4007"],"gpt_icon":0},{"id":"2489108415","title":"阿斯利康中国人事调整，林骁出任阿斯利康中国总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2489108415","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489108415?lang=zh_cn&edition=full","pubTime":"2024-12-05 11:23","pubTimestamp":1733368980,"startTime":"0","endTime":"0","summary":"南方财经12月5日电，记者获悉，阿斯利康新任全球执行副总裁、国际业务负责人Iskra Reic发布内部信宣布，林骁出任阿斯利康中国总经理，关冬梅出任阿斯利康中国肿瘤业务总经理。林骁和关冬梅将分别成为生物制药业务部和肿瘤业务部全球管理团队成员。林骁、关冬梅，以及阿斯利康中国副总裁，罕见病事业部负责人胡轶清，都将直接向阿斯利康全球执行副总裁、国际业务负责人Iskra Reic汇报。此外，据阿斯利康对记者披露，赖明隆担任阿斯利康全球肿瘤业务Dato-DXd及肺癌事业部负责人，向阿斯利康全球高级副总裁，肿瘤业务部负责人Sunil Verma先生汇报。（21世纪经济报道）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205112318ab5ea269&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205112318ab5ea269&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","BK4585","AZN","BK4588","BK4007","LU2417539215.USD","LU2462157665.USD","LU2456880835.USD","LU1829250122.USD","LU2236285917.USD","BK4568","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2489310841","title":"阿斯利康宣布任命Iskra Reic为国际执行副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2489310841","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489310841?lang=zh_cn&edition=full","pubTime":"2024-12-05 10:44","pubTimestamp":1733366648,"startTime":"0","endTime":"0","summary":"近日，阿斯利康在官网发布人事公告。宣布任命 Iskra Reic 为国际执行副总裁 、国际业务负责人，全面负责包括中国、亚洲和欧亚市场、中东和非洲、拉丁美洲、澳大利亚和新西兰在内的这一广袤地区整体战略，推动业务实现可持续增长。Iskra将接替王磊，王磊因在中国接受调查而继续暂离工作岗位。近期，Iskra负责新成立的阿斯利康疫苗和免疫疗法业务部，成功使其成为疾病预防新时代的领头羊。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120510462598e57d8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120510462598e57d8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU2417539215.USD","BK4588","LU0889565916.HKD","BK4585","AZN","LU1829250122.USD","BK4007","LU2236285917.USD","LU2462157665.USD","LU0109394709.USD","LU2456880835.USD","LU0320765992.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0409},{"period":"1month","weight":0.0197},{"period":"3month","weight":-0.1807},{"period":"6month","weight":-0.1805},{"period":"1year","weight":-0.0191},{"period":"ytd","weight":-0.0402}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.483871,"avgChangeRate":-0.001106},{"month":2,"riseRate":0.387097,"avgChangeRate":-0.020166},{"month":3,"riseRate":0.580645,"avgChangeRate":0.030042},{"month":4,"riseRate":0.677419,"avgChangeRate":0.03301},{"month":5,"riseRate":0.516129,"avgChangeRate":0.008567},{"month":6,"riseRate":0.46875,"avgChangeRate":0.020173},{"month":7,"riseRate":0.59375,"avgChangeRate":-0.004027},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002026},{"month":9,"riseRate":0.5625,"avgChangeRate":0.002514},{"month":10,"riseRate":0.53125,"avgChangeRate":0.013465},{"month":11,"riseRate":0.5,"avgChangeRate":-0.000033},{"month":12,"riseRate":0.5625,"avgChangeRate":0.007557}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}